

特別無料セミナー・世界の医薬品研究開発とディール活動の最前線
 タイムテーブル（東京 2/21・大阪 2/23 共通）

* 講演内容および時間は変更になる場合があります。予めご了承ください。

Time	Session
13:30-14:00	受付（Registration）
14:00-14:05	開会の挨拶（Welcome and Opening Remarks）
14:05-14:40	<p>講演 1：基調講演 – 低分子医薬品の現状分析(仮題)(日本語・35分) 戸邊雅則様 – 主任研究員 博士(理学) / 日本製薬工業協会・医薬産業政策研究所</p>
14:45-15:30	<p>講演 2：世界の医薬品の臨床研究・開発をめぐる最新動向(英語・45分) Ian Lloyd - Senior Director, Pharmaprojects and Data Integration / informa</p> <p>The size of the pharmaceutical R&D pipeline has been growing inexorably in recent years, despite stuttering success at bringing new drugs to the market. This presentation will look at the direction of travel and the contents of the pipeline in early 2018. It will look at the winners and losers and use data going back over a number of years to extract slow-burning trends. Using content from Informa’s Citeline suite of products including Pharmaprojects, Trialtrove and Sitetrove, some of the areas which will be examined include:</p> <ul style="list-style-type: none"> • New drug launches 2017 – was it a vintage year? • Which big pharma companies advanced and which retreated, and is big pharma increasing its dominance, or is pharma fragmenting further? • The landscape of clinical candidates, and trends in the conduct of clinical studies • Biotech vs small molecules – who’s winning? • Is there more novelty in the industry, or are firms playing it safe? • Is the rare disease boom set to continue? <p>As well as reviewing what trends in the historical pipeline can tell us, the talk will look forward into 2018 and highlight what to watch for, both in terms of the drugs which might come to market, and the issues which the industry is likely to face in the twelve months ahead.</p>
15:30-16:15	<p>講演 3：5つの代表的疾患領域におけるディールトレンド – 世界の製薬企業トップ 20 を見る(英語・45分) Amanda Micklus - Principal Analyst, Datamonitor Healthcare / informa</p> <p>The top 20 global pharmaceutical companies actively conduct business development transactions across the key therapy areas of diabetes, neurology, pain, autoimmune disease, and oncology. Dealmakers are innovating in each of these areas in different ways, looking to take advantage of multiple opportunities while realizing the changes that each market is undergoing. Based on an examination of ten-year, top-level deal trends in alliances and therapeutically driven bolt-on</p>

	<p>acquisitions, as well as a look at individual key transactions, the presentation aims to understand how the top 20 pharma peer set is preparing for future competition in these therapy areas.</p> <p>Selected datapoints examined, based on Informa's Medtrack, Strategic Transactions, PharmaVitae Analytics, and In Vivo:</p> <ul style="list-style-type: none"> •Impact of externalization on revenue, contrasted with revenue based on internal drug development •Top-level alliance volume and value (up-front and total potential value) by therapy area over a ten-year period, with compare/contrast of two five-year timeframes, 2008–12 and 2013–17 •Deal-making trends across each therapy area, including volume, value, phase, and in- and out-licensing split for certain therapy areas •Bolt-on acquisitions
16:15-16:30	コーヒーブレイク (15分)
16:30-16:55	<p>講演 4 : インフォーマ・ファーマインテリジェンス 主要製品開発・機能拡張プランのご紹介(英語・25分)</p> <p>Nicola Marlin - Vice President, Product Marketing / Informa</p>
16:55-17:20	<p>講演 5 : 課題解決ケーススタディー – 具体的な事例を挙げて(英語・25分)</p> <p>Timothy Pang - Senior Director, Pharma Consulting / Informa</p>
17:20-17:25	閉会の挨拶 (Closing Remarks)
17:30-19:00	懇親会 (Reception)